Cyclooxygenase-2 gene transcription in a macrophage model of inflammation.
Infections involving LPS-bearing, Gram-negative bacteria can lead to acute inflammation and septic shock. Cyclooxygenase-2 (COX-2), the target of nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors, is importantly involved in these responses. We examined the dynamics of COX-2 gene expression in RAW264.7 murine macrophages treated with LPS as a model for COX-2 gene expression during inflammation. We established, using Northern blotting, nuclear run-on assays, and RT-PCR, that COX-2 transcriptional activation continues for at least 12 h after LPS treatment and involves at least three phases. Previous studies with murine macrophages identified an NF-kappaB site, a C/EBP site, and a cAMP response element-1 (CRE-1) as cis-acting elements in the COX-2 promoter. We identified three additional functional elements including a second CRE (CRE-2), an AP-1 site, and an E-box that overlaps CRE-1. The E-box mediates transcriptional repression whereas the other cis-elements are activating. Using electrophoretic mobility supershift and chromatin immunoprecipitation assays, we cataloged binding to each functional cis element and found them occupied to varying extents and by different transcription factors during the 12 h following LPS treatment. This suggests that the cis elements and their cognate transcription factors participate in a sequential, coordinated regulation of COX-2 gene expression during an inflammatory response. In support of this concept, we found, using inhibitors of Jun kinase and NF-kappaB p50 nuclear localization, that COX-2 gene transcription was completely dependent on phospho-c-Jun plus p50 at 6 h after LPS treatment but was only partially dependent on the combination of these factors at later treatment times.
Kang
Yeon-Joo
YJ
Cell and Molecular Biology Program, Michigan State University, East Lansing, MI 48824, USA.
Wingerd
Byron A
BA
Arakawa
Toshi
T
Smith
William L
WL
D000818:Animals; D015152:Blotting, Northern; D002460:Cell Line; D051546:Cyclooxygenase 2 / Q000235:genetics*; D004195:Disease Models, Animal; D024721:E-Box Elements / Q000276:immunology; D024202:Electrophoretic Mobility Shift Assay; D015870:Gene Expression; D005786:Gene Expression Regulation / Q000276:immunology*; D047468:Immunoprecipitation; D007249:Inflammation / Q000235:genetics*; D008070:Lipopolysaccharides / Q000276:immunology; D008264:Macrophages / Q000276:immunology*; D051379:Mice; D018448:Models, Immunological; D011401:Promoter Regions, Genetic; D016755:Proto-Oncogene Proteins c-jun / Q000276:immunology / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018808:Transcription Factor AP-1 / Q000276:immunology / Q000378:metabolism; D014158:Transcription, Genetic; D014162:Transfection
D008070:Lipopolysaccharides; D016755:Proto-Oncogene Proteins c-jun; D018808:Transcription Factor AP-1; D051546:Cyclooxygenase 2